Steven Cohen Iveric Bio, Inc. Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $4,854 - $7,331	185 New	185 $7,000
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $55.4 Million - $72.9 Million	-2,967,729 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $40.7 Million - $56.5 Million	2,360,829 Added 389.0%	2,967,729 $63.5 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $5.7 Million - $11.3 Million	606,900 New	606,900 $10.9 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.